Articles by Adeline Siew, PhD - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Adeline Siew, PhD

Adeline Siew, PhD


Adeline Siew is the editor of Pharmaceutical Technology Europe.

Articles
Single-Use Technology in Downstream Processing
March 1, 2014

Experts discuss the advances in single-use technology for downstream bioprocessing applications.

Elucidating Biosimilars Characterization
September 1, 2013

Review the importance of characterization studies during biosimilars development and related analytical methods.

Gauging the Outlook of the Biologics Market
September 1, 2013

Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.

Scientists Discover New Targets for Breast Cancer
July 29, 2013

Scientists at A*STAR's Genome Institute of Singapore (GIS) have identified genes that could be potential targets for anticancer agents in the treatment of aggressive breast cancer.

Adaptimmune Initiates Phase I/IIa Clinical Trial in Ovarian Cancer
July 26, 2013

Adaptimmune has opened a Phase I/IIa ovarian cancer trial to evaluate its genetically engineered T cell treatment, with enhanced antitumor activity.

CPhI Pharma Insights: Formulation and Ingredients Report
July 25, 2013

The report highlights a need for greater third party certification to ensure GMP vigilance.

Seattle Genetics Forms ADC Pact with Bayer
July 3, 2013

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013

Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor (EGFR) antibody approved by FDA for the treatment of metastatic colorectal cancer.

Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013

Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor (EGFR) antibody approved by FDA for the treatment of metastatic colorectal cancer.

ADVERTISEMENT

ADVERTISEMENT

Click here